Global Allergen-Specific Immunotherapy (AIT) Industry Development: Precision Immune Regulation and China’s Breakthrough in Precision Allergy Care
View our Complimentary Blue Book
Allergen-Specific Immunotherapy (AIT), as the only etiological treatment that can alter the natural course of allergic diseases by inducing immune tolerance, stands at the core of long-term management for allergic rhinitis, asthma, atopic dermatitis and other prevalent allergic disorders. Driven by surging global prevalence of allergies, breakthroughs in molecular allergens and recombinant allergens, and continuous iteration of delivery technologies, the AIT industry is entering a pivotal era shifting from empirical treatment to precision immune regulation. Supported by technological upgrading, expanded patient awareness, and flexible market access pathways such as Named Patient Programs (NPP), the global AIT market is expanding steadily, with next-generation precision products and novel delivery systems rising rapidly. Meanwhile, China’s AIT industry, backed by a huge patient population, enhanced local R&D capabilities, and accelerated industrialization, is increasingly becoming a key growth engine and emerging force in the global AIT landscape.
Download this complimentary Blue book to discover:
Industry Overview and AIT Landscape:
A comprehensive introduction to AIT, including core definitions, century-long development history, mechanism of immune tolerance induction, and classification of technologies and administration routes, laying a solid foundation for understanding AIT as the only etiological therapy for allergic diseases.
Global and China AIT Industry and Future Outlook:
An in-depth analysis of the global and Chinese AIT industry, covering epidemiological drivers, growth potential, competitive patterns, and regional development differences, revealing huge unmet needs and long-term growth logic.
Technology and Product Analysis of AIT:
A systematic breakdown of four generations of AIT technologies (natural extracts, allergoids, molecular allergens, recombinant allergens) and mainstream administration routes (subcutaneous SCIT, sublingual SLIT, intradermal IDIT, and emerging technologies such as microneedles and oral dissolvable films), highlighting differentiated technical advantages and clinical value.
Unmet Clinical Needs, Market Drivers and Future Trends:
A forward-looking assessment of the AIT industry, focusing on core clinical pain points, key driving forces, and development trends toward higher efficacy, safety, compliance and accessibility, with a special emphasis on China’s accelerated catching-up and industrialization breakthrough.
Profiles of Leading AIT Enterprises Worldwide:
Showcasing global and Chinese AIT pioneers and their core technologies, product pipelines and commercialization layout, including ALK‑Abelló, Stallergenes Greer, Allergopharma, Allergy Therapeutics, China’s Worg Pharmaceuticals and Wolwo Pharmaceuticals.
Default PDF Reader
Register to Download the Blue Book To-go
60 YEARS OF INSIGHTS
Our Global Initiatives
ABOUT THE ANALYST
Kim He
Senior Project Manager of Frost & Sullivan China, participated in market research projects，focusing on medicine, medical device and medical service.
About Our Firm
Frost & Sullivan